Home/Pipeline/MM012

MM012

Undisclosed

DiscoverYActive

Key Facts

Indication

Undisclosed

Phase

DiscoverY

Status

Active

Company

Mucommune

About Mucommune

Mucommune is a private, preclinical-stage biotech based in Cambridge, MA, and the Research Triangle, NC, with roots in academic research from Johns Hopkins and UNC. The company has evolved into a unique R&D engine, successfully spinning off Inhalon Biopharma, and now manages three core technology platforms: Elleon for female reproductive health, Polyon for polymer immunogenicity, and a stealth in vivo cell engineering platform for cancer and autoimmune diseases. Its strategy focuses on transforming early scientific discoveries into clinical-stage assets, supported by recent non-dilutive funding like an ARPA-H award for in vivo CAR-T development.

View full company profile

Therapeutic Areas

Female Reproductive Health Oncology Autoimmune Diseases Infectious Diseases

Other Undisclosed Drugs

Drug	Company	Phase	Status
Preclinical ISAC 1	Bolt Biotherapeutics	Preclinical	Available for Partnering
Preclinical ISAC 2	Bolt Biotherapeutics	Preclinical	Available for Partnering
ART12.11	Artelo Biosciences	Preclinical	Active
Novel Vaccines	MSD	Development	Active
SLS-009	Seelos Therapeutics	Discovery	Research
Technosphere Platform (New Formulations)	MannKind	Discovery/Preclinical	Active R&D
Measovir®-based Prophylactic Vaccine (with Unither)	Oncovita	Research/Pre-clinical	Early-stage collaboration
Internal sdAb Discovery Program	NanoTag Biotechnologies	Discovery	Active
NB-701	Nerai Biosciences	Discovery	Active
Undisclosed Therapeutic Program(s)	Bright Cell	Clinical Trial (Phase unspecified)	Active
Biosimilars Pipeline	Intelligent Therapeutics	Pre-clinical/Development	Active
Proprietary Therapeutic Pipeline	Excelsior Sciences	Discovery	Active